Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standard treatments.
INTRODUCTION
Pancreatic cancer which include Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic neuroendocrine tumors (PNETs) is the fourth most common cause of cancer deaths worldwide (1) . PDAC is a highly aggressive cancer with a very poor prognosis and an overall 5-year survival rate less than 5%. Current therapies in PDAC and PNET, consist solely of surgery followed or not by targeted or chemo therapies (2, 3) .
Nucleolin (NCL) is highly expressed in several types of cancer (4) , and is a cancer specific target, being localized at the cell surface of tumor cells and activated endothelial cells (ECs) (5) (6) (7) . Nucleolar NCL principally regulates rRNA transcription and ribogenesis while cell surface NCL acts as a low affinity receptor for specific ligands (4) . Moreover, NCL stabilizes the mRNA of anti-apoptotic proteins (8) . NCL is a novel target for anticancer therapy as demonstrated by the effects of several NCL-targeting molecules (9) (10) (11) . We recently developed a multivalent synthetic pseudopeptide N6L that selectively binds to NCL (9) . N6L strongly inhibits breast cancer growth by inducing apoptosis of tumor cells and is currently in preparation for phase II clinical trials (9) (IPP-204106). Interestingly, N6L as well as a NCL blocking antibody impairs both experimental and in vivo angiogenesis by targeting endothelial cells and tumor vessels (9, 12, 13) . The mechanisms of regulation of tumor angiogenesis by NCL are poorly described, such as the effect of NCL inhibition in tumor cells and stroma of pancreatic cancer.
Several molecules that regulate tumor angiogenesis are overexpressed in pancreatic cancer. In human PDAC, VEGF expression is increased and high levels of Ang-2 correlate with metastatic spread and poor survival of PDAC patients (14, 15) . However, blood vessels in PDAC are compressed by the fibrous stroma and PDAC is poorly perfused with a consequent aberration in local blood flow and oxygenation (16) . This contributes to the promotion of cancer growth, tumor hypoxia, metastasis formation and prevents an efficient delivery of 4 chemotherapeutic drugs (17, 18) . PNETs, differently from PDAC are highly vascularized, but share the same vascular abnormality phenotype that contributes to cancer progression and metastatic dissemination (3) .
Based on these findings our aim was to target both cancer cells and tumor vasculature in pancreatic cancer. In this work, we studied NCL-targeted therapy, demonstrating that N6L, hampers pancreatic cancer growth and metastasis by dually targeting cancer cell growth and tumor vasculature, and we explored the potential mechanisms of action.
MATERIALS AND METHODS
The source of antibodies (Abs) and the experimental procedures not described herein are detailed in Supplementary Data. 
Cell culture

Tumor mouse models
FVB/n syngenic mice were injected orthotopically in the pancreas with mPDAC cells (10 3 cells/mouse in 50 µL). In this mPDAC model, we first established that the tumors reach a 5 volume of approximately 80 mm 3 within a week following injection of tumor cells. We defined this time period as the starting point to perform a regression trial, and one week after cell inoculation, mice were treated 3 times a week for the duration of 3 weeks by intraperitoneal injections (i.p.) with either N6L (10 mg/kg) or vehicle (saline solution) as a control. Gemcitabine was injected in the tail vein (i.v.) (100 mg/kg) 2 times a week as indicated. In the combination treatment, GEM was injected 2 times (i.v.) a week and N6L 3 times a week (i.p.) after 1 week of N6L for a total of 2 weeks to the animals. Regarding the measurement of metastasis, livers from PDAC mice were entirely cut and sections spaced of 200 µm were stained by hematoxylin. Images were taken by Scanner Aperio Scanscope CS.
The metastatic surface of each nodule in the liver sections was measured, and the total surface occupied by metastasis was divided by the total area of the liver section.
The RIP-Tag2 transgenic mouse model has been previously described (19) , mice were treated by N6L 10 mg/kg, 3 times a week for a duration of 4 weeks from 12 to 16 weeks of age.
Mice were sacrified and total tumor burden was quantified as previously described (9) . All in vivo experiments were carried out with the approval of the appropriate ethical committee and under conditions established by the European Union.
TMA staining and analysis
An immunohistochemical staining was performed with anti-nucleolin antibody (Supplementary methods) using standard protocol in 47 human PDAC included in a tissuemicroarray (TMA) paraffin block. Immunostaining was performed using an automatized technique (Streptavidin-peroxydase with an automate Bond Max, Leica), and slides were counterstained with hematoxylin. Images were taken by the Scanner Aperio Scanscope CS.
Analysis of NCL staining was performed by a score determination corresponding to the intensity of the labeling of tumor cells from 0 to 3 (0, no staining; 1, low staining; 2, moderate 6 staining; 3, high staining) in each spot. The final score for each tumor was the average of the scores obtained for each spot available by tumor.
Measurement of tumor delivery of doxorubicin and vessel perfusion
To evaluate tumor vessel perfusion, 0.05 mg FITC-labeled tomato lectin (Vector laboratories, CA, USA) were injected i.v. into PDAC-carrying mice, as previously described (20) . After 10 minutes, the animals were euthanized, and lectin distribution was visualised by fluorescent confocal microscopy.
To measure the tumor delivery of doxorubicin mice were injected with 10 mg/kg doxorubicin hydrochloride (Sigma-Aldrich) via the lateral tail vein 4 hours before sacrifice. Tumors and kidneys as controls were collected from each mouse and weighted. Samples were resuspended in a lysis buffer (0.25 M sucrose, 5 mM TrisHCl pH 7.6, 1 mM MgSO 4 , 1 mM CaCl 2 ) and homogenized in an ice-cold Potter homogenizer. 200 µl of each homogenate was placed into a new microcentrifuge tube containing 10% Triton X-100 and 1.5 ml acidified isopropanol, mixed and kept at -20°C overnight. Samples were centrifuge at 15,000 g for 20 minutes.
Doxorubicin was quantified by spectrophotometric analysis at 590 nm using TECAN Infinite M1000 plate reader (Tecan, Durham, NC). These values were calculated as the fluorescence/weight ratio of the tumor divided by the fluorescence/weight ratio of the kidney and expressed as µ equivalents/g tissue of doxorubicin. Data are mean ± SD of triplicate aliquots from tumor homogenates.
Cell transfection and cell migration
Cell transfection by siRNA was performed by following manufacturer instructions (Hiperfect, Qiagen), for siRNA sequences see Supplementary methods.
For pericyte motility, 9x10 4 HUVECs per well were seeded in 6-well plate. The day after, HUVECs were transfected with 10 nM siRNA or treated with 30 µM N6L. Three days later
HUVECs were washed and medium was replaced by EBM-2. Cell supernatant was collected 1 hour after. 20x10 4 HBVPs were seeded in the upper chamber (with or without 400 ng/mL recombinant Ang2) coated with 1.5 ug/mL collagen type I and the EC supernatant was added in the lower chamber. For each transwell, nuclei of cells from 5 fields were counted using Leica Aristoplan microscope equipped with a CoolSNAP CCD camera.
Statistics
Unless indicated otherwise, bars represent mean +/− Standard Error Mean (S.E.M.) (n≥3), pvalues have been calculated using a two-tailed or one-tailed unpaired t test using GraphPad Prism software. *p < 0.05; **p < 0.01; ***p < 0.001; ****p<0.00001. P values of the KaplanMeier curve of survival has been calculated by using the Long-rank (Mantel-Cox) test.
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RESULTS
NCL is a potential new target of tumor progression in PDAC.
NCL is overexpressed in tumors and its inhibition hampers breast, prostate, and melanoma cancer growth and angiogenesis (4) . To evaluate NCL as a potential target in human PDAC, we analyzed NCL protein expression levels in 47 tumors included in tissue microarray. 74.5%
of the tumors showed a moderate (Fig. 1C) or high NCL staining (Fig. 1A and, B arrows) .
Non-tumoral pancreas, corresponding to pancreatitis (Fig. 1D ), normal peritumoral tissue or normal ducts either around or included in the tumors (Fig. 1B, arrowheads) were not or very faintly stained by anti-NCL antibody. Next, we checked the correlation between NCL expression level and overall survival (OS) in patients with PDAC. Notably, the OS significantly increased in PDAC patients with low levels of NCL compared to patients with high levels of this protein (Fig. 1E ). Fig 1D) , and the active caspase-3 levels increased after 48 hours of treatment ( Supplementary Fig. 1E ). Moreover, N6L strongly inhibited the migration of MIA PaCa2 and mPDAC cell lines by 69% and 72%, respectively, compared with controls ( Supplementary Fig. 1F ), and the invasion of mPDAC cells toward a 9 layer of matrigel, as compared to controls ( Supplementary Fig. 1G ). The implication of NCL in PDAC cell proliferation was tested by other experimental approaches. For instance, the viability of mPDAC cells was decreased by a NCL blocking antibody (MS3) (Supplementary Fig. 2A) . Moreover, the knock down of Ncl in mPDAC by means of CRISP-Cas9 technology caused massive death of the cells (Supplementary Fig. 2C ). NCL blocking antibody pretreatment decreased the efficacy of the entry of Alexa546-N6L in PDAC cells ( Supplementary Fig. 2B ). In line with these results, the combination of NCL blocking antibody and N6L did not show a cumulative effect on cell viability (Supplementary Fig. 2A ).
These results suggested that N6L and NCL blocking antibody competed for NCL targeting in PDAC cells.
N6L treatment hampers PDAC growth and liver metastasis.
Based on the high levels of NCL found in human PDAC, and according to the observation that N6L inhibited hPDAC and mPDAC cell proliferation, we decided to assess the anti- 3D ) and regions with a higher vessel density (arrowheads in Supplementary Fig. 3D ).
Notably, carbonic anhydrase 9 (CA9) expression significantly increased in parallel with enhanced synthesis of collagen I during cancer progression in mPDAC (Supplementary Two ways of dissemination to the liver are described in PDAC patients, through vessels and through a peritoneal dissemination. mPDAC model developed liver metastasis prominently in the liver at close contact to the peritoneal surface ( Fig. 2G , arrows). The total metastatic area was quantified (Fig. 2H ). Remarkably, N6L strongly reduced liver metastasis area by 67% ( Fig. 2G and H). These findings are further supported by our data describing a strong effect of N6L in blocking the motility and the invasion of mouse and tumor cell lines (Supplementary Fig. 1F and G).
NCL targeting by N6L normalizes tumor vessels and counteracts tumor hypoxia in PDAC and PNET.
Since NCL targeting inhibits EC growth and NCL is significantly expressed in the vasculature 11 of mPDAC, we investigated the effect of N6L on tumor blood vessel density and morphology.
Vessel density and vessel branching were significantly decreased in N6L-treated mPDAC by 42% and by 62%, respectively ( Blood vessel perfusion is a parameter of vessel homeostasis and correlates with pericyte coverage and oxygenation (25) . Interestingly, the treatment of mPDAC with N6L enhanced the perfusion of the tumor vasculature, compared with controls ( Fig. 3F and G) . Next, we assessed whether the tumor oxygenation levels were affected by N6L. In line with its normalizing effect, N6L reduced the hypoxic area, detected by pimonidazole staining (Fig.   3H ). In addition, N6L strongly inhibited the expression of carbonic anhydrase 9 (CA9), a marker of hypoxia (26) (Fig. 3I and J).
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To better assess the effects of N6L on tumor vessel normalization and the related anti-tumor properties, we employed a transgenic mouse model of pancreatic neuroendocrine tumor (PNET) RIP-Tag2. This model has been widely used to assess the efficacy of several antiangiogenic compounds and to evaluate the effect of vessel normalization to block tumor growth and invasion (19, 24) . To this aim, we performed a regression trial (24), treating a cohort of tumor-bearing RIP-Tag2 mice with N6L. This treatment showed an inhibition of tumor growth by 40% (Fig. 4A ) and an increase of tumor cell apoptosis by 90% ( All together these results demonstrate that the inhibition of NCL induces vessel normalization in two different mouse models of pancreatic cancer by increasing pericyte coverage, vessel perfusion and reducing intra-tumoral hypoxia.
NCL inhibition affects EC activation and Ang-2 secretion.
The mechanisms of tumor inhibition and vessel normalization by N6L were further studied.
N6L does not induce apoptosis of ECs (15), and did not change the viability value of confluent ECs ( Supplementary Fig. 5A ), suggesting that NCL inhibition specifically target proliferating and activated ECs. N6L significantly decreased the percentage of ECs in S phase when compared to control-treated cells (14% vs 27%) and increased the percentage of cells in G1 (64% vs 47%) (Fig. 5A ). The involvement of NCL in EC cycle progression was further confirmed by depleting NCL in ECs. In fact, NCL depletion by siRNA significantly decreased the percentage of ECs in S phase, and increased the amount of cells in G1 phase when compared to control ECs (4% vs 32% and 86% vs 42%, respectively) (Fig. 5B ).
Another feature of EC activation is the secretion of pro-angiogenic molecules by ECs (27) .
Therefore, we evaluated the effect of N6L on the basal secretion of angiogenic-related molecules by ECs by using a proteome angiogenesis antibody array (R&D). Interestingly, among the different secreted pro-angiogenic factors, we observed that Ang-2, shown to promote tumor progression and whose inhibition induces vessel normalization (28) (29) (30) (31) (32) , was inhibited by N6L treatment (Supplementary Table 1 ). Based on this screening we analyzed the effect of N6L on the secretion of Ang-2 by ECs. Ang-2 level decreased in the EC supernatant upon 5 hours of N6L treatment but not in EC lysates (Fig. 5C ). Ang-2 is stocked in Weibel and Palade bodies (WPBs) and basally secreted by WPB exocytosis in activated ECs (33) . Ang-2 colocalized with the WPB protein vWF in ECs (Fig. 5D, inset) . Interestingly, 5 hours of N6L treatment enhanced Ang-2 content (Fig 5D and E) , indicating that N6L
interferes with the turnover of Ang-2 secretion, accumulating this protein into ECs. The importance of NCL in Ang-2 secretion inhibition under N6L was tested (Fig 5F) . While significant inhibition of secreted Ang-2 has been observed in siControl ECs treated with N6L, no detectable differences in Ang-2 levels were measured in siNCL-EC supernatants, compared with their respective controls (Fig. 5F ). The effect of longer N6L treatment (72 hours) on Ang-2 expression was analyzed (Fig 5H an I) . Ang-2 level decreased in EC lysates at the protein level (Fig 5H) and at the mRNA level (Fig 5I) under N6L treatment.
Coherently, Ang-2 basal secreted levels ( Fig. 5F ) and Ang-2 protein level in ECs (Fig. 5G) were also decreased in NCL-depleted cells. These data suggest that NCL inhibition affects Ang-2 secretion and expression. In line with the observed pro-normalizing effect of N6L, among angiogenic-related secreted molecules in ECs, we observed that PDGFβ, a factor mediating pericyte recruitment (34), was also upregulated by N6L, (Supplementary Table 1) and its mRNA was significantly increased under N6L treatment ( Supplementary Fig. 5B ).
14 Together these data demonstrate that NCL depletion or inhibition by N6L affects EC activation by decreasing the percentage of cells in S phase and regulating angiogenic molecules involved in pericyte recruitment.
NCL inhibition decreases plasma Ang-2 level in PDAC model.
In human cancers Ang-2 is highly expressed by ECs in tumor blood vessels and tumor cells (35, 36) . Notably, Ang-2 is expressed mostly in tumor blood vessel of PDAC model ( Supplementary Fig 5D) . Pilot studies aimed to measure the time-course of plasmatic Ang-2 amount showed that the levels of Ang-2 in the plasma were unchanged until the second week of PDAC growth and increased then after ( Supplementary Fig 5E) . Based on these preliminary data, we next analyzed plasmatic Ang-2 level of different mice injected by PDAC cells or saline solution after three weeks of inoculation ( Fig 6A) . As expected from our previous observation, Ang-2 was significantly increased in tumor bearing mice (Fig. 6A) . To evaluate the effect of N6L-treatment on secreted Ang-2 levels in vivo, we checked the plasma of control and N6L-treated mPDAC at the end of the treatment. Remarkably, Ang-2 was significantly decreased by 68% in the plasma of N6L-treated mice compared with control ( Fig. 6B) , while PDGFβ level did not change ( Supplementary Fig. 5G ). In parallel, Ang-2 expression was evaluated in tumors. Since tumor vessel density was decreased in N6L-treated mPDAC ( Fig. 3A and B) , Ang-2 expression was normalized to the tumor vessel gene MECA32 and Fig 6C shows that Ang-2 expression decreased under N6L treatment. Notably, VEGF signaling was not affected by N6L, since VEGF-A expression ( Supplementary Fig. 5F ) was unchanged in N6L-treated PDAC tumors, and VEGFR2 levels was not affected in N6L-treated ECs (Supplementary Fig. 5C ).
To better assess the role of secreted Ang-2 in vessel normalization, we sought to investigate whether decreased Ang-2 secretion by Ang-2-depleted or N6L-treated ECs was sufficient to 15 induce pericyte recruitment. Pericyte migration toward the supernatants of Ang-2-depleted ECs was strongly increased compared with control (Fig. 6D) . Moreover, pericyte migration towards the supernatant of ECs treated with N6L was similarly increased (Fig 6E) . Since pericytes express the Ang-2 receptor Tie-2 and Ang-2 induces dose-dependent pericyte loss on retina vessels (37), we investigated if Ang-2 could directly affect pericyte migration. Ang-2 functions are dependent to the context of angiogenic cytokines or factors regulating pericyte response (37) . Recombinant Ang-2 did not affect alone the migration of control pericytes, as previously shown (37) . However, recombinant Ang-2 significantly reduced the increased pericyte migration towards the supernatants of Ang-2-depleted ECs (Fig. 6D ) or N6L-treated ECs (Fig 6E) . Together these data demonstrate the crucial involvement of Ang-2 in the pronormalizing effect induced by N6L.
N6L enhances drug delivery in PDAC treatment.
It has been shown that tumor vessel normalization represents a remarkably advantageous anticancer strategy, being also able to enhance drug delivery and, consequently, chemotherapy efficacy (23). To first assess whether the enhanced perfusion induced by N6L could also increase drug delivery, doxorubicin was injected in the tail vein of control or N6L-treated mice at the end of the trial and the amount of drug present into the tumor tissues was quantified. In line with the normalized vessel phenotype, N6L treatment increased by 3.5 times the efficacy of the doxorubicin delivery to the tumors of mPDAC, compared to controls (Fig. 7A) . The resistance of PDAC tumors to chemotherapies, and consequently the extremely bad prognosis for PDAC patients is at least partly due to the extremely poor perfusion of blood vessels and drug delivery (38, 39) . Increasing drug delivery represents a key strategy to treat PDAC patients. To evaluate whether the effect observed in mouse tumors was also observed in human cancers, both human BxPC-3-derived orthotopic (Fig. 7B ) and subcutaneous ( Supplementary Fig. 5H ) xenograft tumors were treated with N6L and doxorubicin was injected and quantified at the end of the treatment. N6L-treatment significantly increased the delivery of the drug into the tumor similarly to the mPDAC ( Fig.   7B and Supplementary Fig. 5H ). The time course of N6L treatment necessary to increase doxorubicin delivery induced by N6L was evaluated by a treatment of one or two weeks in subcutaneous BxPC-3 ( Supplementary Fig. 5H ). The improvement of the doxorubicin delivery by N6L was clearly improved by kinetics between the first and the second week of treatment ( Supplementary Fig. 5H ). Stemming from these data we sought to investigate whether the pre-treatment of N6L was able to enhance the anti-tumor effect of gemcitabine, the standard of care for PDAC human patients. Our preliminary data in mPDAC showed that the dose of 2 mg/kg N6L impaired tumor growth with less efficacy compared to the dose of 10 mg/kg, but was still able to induce pericyte coverage of tumor vessels (Fig 7C and   Supplementary Fig. 4A ). This suboptimal anti-tumor dose was therefore used to test the effects of the combination of N6L and gemcitabine in mPDAC model. Gemcitabine and N6L used as single agents had a similar effect in reducing tumor growth. Remarkably, the pretreatment of mPDAC with N6L and the subsequent treatment with the combination of N6L with gemcitabine showed a greater effect in decreasing tumor volume in mPDAC, by 75% compared to the single treatments and by 82% compared to the control (Fig. 7C ).
DISCUSSION
NCL inhibition is known to reduce tumor growth, and different strategies of NCL-targeted therapy are in development for clinical application in renal cell cancer and breast cancer (10, 11) . In this study we described for the first time NCL-targeted therapy in pancreatic cancer.
We NCL is a marker of angiogenic vessels (7) tumor models (28) (29) (30) (31) (32) . Based on these observations, we can argue that the observed pronormalizing effect of N6L on tumor vasculature could be in part mediated by the inhibition of Ang-2 during the treatments. Notably, we observed that the depletion of Ang-2 and the inhibition of secretion by N6L in ECs are sufficient to promote pericyte migration. Since recombinant Ang-2 is able alone to rescue these effects, we could argue that the regulation of Ang-2 expression and secretion by ECs is crucial for pericyte recruitment. These findings suggest that the arrest of the EC cell cycle, along with the reduction of Ang-2 level in vivo, could contribute to the anti-angiogenic and pro-normalizing effect of NCL inhibition observed in mPDAC and RIP-Tag2 mice.
Single-agent gemcitabine is the standard-of-care treatment for PDAC patients, but the addition of targeted therapies to chemotherapy failed to show any improvement (47) . One possible novel strategy to improve the current therapy in PDAC is to enhance drug delivery by targeting tumor microenvironment (39, 48, 49) . However, decrease of PDAC solid stress by Shh deletion or Smoothened inhibition, increased vascular density, which in turn accelerated tumor growth and promoted metastasis (48) . Interestingly, while the antiangiogenesis therapies fail to improve PDAC survival, VEGFR inhibition was capable to counteract tumor angiogenesis induced by reduction of stroma stiffness (48) . There is a growing body of evidences highlighting, both in pre-clinical and clinical settings, the importance of tumor vessel normalization, described by Jain and colleagues (23, 50) . It has been demonstrated that the strong reduction of tumor hypoxia and the enhancement of vessel perfusion, accompanied by improved drug delivery, is a great advantage of using a pro- Mean metastatic liver fraction (%) * T T P P P P P P P P P P P P P P P 
